Simvastatin Reduces Circulating Osteoprotegerin Levels in Patients With Type 2 Diabetes

• Status: Completed
• Trial end date: 1993-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Diabetes is associated with dyslipidaemia leading to generalized atherosclerosis, cardiovascular disease (CVD) and nephropathy. Osteoprotegerin (OPG), a glycoprotein involved in bone homeostasis, has been implicated in the pathogenesis leading up vessel calcification. Furthermore, CVD in diabetics is associated with increased levels of OPG.

Aim: To investigate whether low dose simvastatin treatment (10-20 mg/day) reduces circulating levels of OPG as well as adhesion molecules (VCAM-1; vascular cell adhesion molecule-1, ICAM; intercellular cell adhesion molecule).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Aarhus
• Treatments: Simvastatin

Criteria

Inclusion Criteria:

• Type 2 diabetes

• Persistent microalbuminuria

• Fasting plasma cholesterol > 5.5 mmol/liter

• Fasting plasma triglycerides < 4.5 mmol/liter

• Fasting HbA1c < 10 %

• Fasting serum C-peptide > 0.49 nmol/liter

• Blood pressure < 155/95

Exclusion Criteria:

• Signs of primary kidney disease

• Signs of primary hepatic disease

• Signs of insufficiently treated cardiac disease